This Week in Nephrology — Sep 23, 2026
Welcome to This Week in Nephrology. This week we're covering 10 notable papers spanning kidney transplantation — from insurance-driven access barriers to intentional immune tolerance — glomerular disease diagnostics and immunosuppression, and a cluster of studies on chronic kidney disease risk, diet, drug safety and functional outcomes. Let's dive in. We start with transplantation, where the most… This week's papers: Medicare Advantage Enrollment and Access to Kidney Transplant After the 21st Century Cures Act. — JAMA 2026 Evaluation of eculizumab for the prevention of delayed graft function after kidney transplantation in adults: A randomized, double-blind, placebo-controlled trial. — American Journal of Transplantation 2026 Delayed immune tolerance intentionally achieved years after two-haplotype matched kidney transplantation. — American Journal of Transplantation 2026 Automated chemiluminescence immunoassay for the detection of anti-nephrin autoantibodies. — Kidney International 2026 Rituximab With or Without Avacopan in ANCA-Associated Vasculitis With Severe Renal Involvement. — Kidney International Reports 2026 Approach to Hematuria: Core Curriculum 2026. — American Journal of Kidney Diseases 2026 Safety of Sodium/Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes and CKD. — American Journal of Kidney Diseases 2026 Normoproteic Plant-Dominant Protein Diets, Uremic Toxins, and Gut Microbiota in Patients With Advanced CKD: A Randomized Controlled Trial. — American Journal of Kidney Diseases 2026 Hypertensive Disorders of Pregnancy and Cardiovascular-Kidney-Metabolic Syndrome. — Hypertension 2026 Self-Reported Versus Performance-Based Measures of Physical Function and Mortality Among Patients With Kidney Failure: A Cohort Analysis of the CONVINCE Trial. — American Journal of Kidney Diseases 2026 Listen at AudioScholar